Table 1 Patient baseline demographics and clinical characteristics
Age, years | Median (IQR) | 58 (51–62) |
|---|---|---|
Range | 36–76 | |
Sex, n (%) | Male | 17 (77.3) |
Female | 5 (22.7) | |
Ethnicity, n (%) | White | 17 (77.3) |
Black | 2 (9.1) | |
East Asian | 2 (9.1) | |
South Asian | 1 (4.5) | |
IMDC prognostic risk group, n (%) | Favorable | 1 (4.5) |
Intermediate | 19 (86.4) | |
Poor | 2 (9.1) | |
Baseline peripheral blood NLR | Median (IQR) | 2.38 (1.85–3.74) |
Range | 1.07–7.29 | |
Karnofsky performance status score, n (%) | 100 | 14 (63.6) |
90 | 1 (4.5) | |
80 | 5 (22.7) | |
70 | 2 (9.1) | |
Previous nephrectomy, n (%) | Yes | 15 (88.2) |
No | 7 (11.8) | |
Previous radiotherapy, n (%) | Yes | 2 (9.1) |
No | 20 (90.9) | |
Target lesions per RECIST 1.1, n (%) | 1 | 6 (27.3) |
≥ 2 | 16 (72.7) | |
Most common active sites of metastasis, n (%) | Lung | 19 (86.4) |
Lymph node | 14 (63.6) | |
Bone | 4 (18.2) | |
Liver | 2 (9.1) | |
Sarcomatoid/rhabdoid histology, n (%) | Yes | 6 (27.3) |
No | 16 (72.7) |
